Cargando…

Building resilient cervical cancer prevention through gender-neutral HPV vaccination

The COVID-19 pandemic has disrupted HPV vaccination programmes worldwide. Using an agent-based model, EpiMetHeos, recently calibrated to Indian data, we illustrate how shifting from a girls-only (GO) to a gender-neutral (GN) vaccination strategy could improve the resilience of cervical cancer preven...

Descripción completa

Detalles Bibliográficos
Autores principales: Man, Irene, Georges, Damien, Sankaranarayanan, Rengaswamy, Basu, Partha, Baussano, Iacopo
Formato: Online Artículo Texto
Lenguaje:English
Publicado: eLife Sciences Publications, Ltd 2023
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10365835/
https://www.ncbi.nlm.nih.gov/pubmed/37486822
http://dx.doi.org/10.7554/eLife.85735
_version_ 1785077045120729088
author Man, Irene
Georges, Damien
Sankaranarayanan, Rengaswamy
Basu, Partha
Baussano, Iacopo
author_facet Man, Irene
Georges, Damien
Sankaranarayanan, Rengaswamy
Basu, Partha
Baussano, Iacopo
author_sort Man, Irene
collection PubMed
description The COVID-19 pandemic has disrupted HPV vaccination programmes worldwide. Using an agent-based model, EpiMetHeos, recently calibrated to Indian data, we illustrate how shifting from a girls-only (GO) to a gender-neutral (GN) vaccination strategy could improve the resilience of cervical cancer prevention against disruption of HPV vaccination. In the base case of 5-year disruption with no coverage, shifting from GO to GN strategy under 60% coverage (before disruption) would increase the resilience, in terms of cervical cancer cases still prevented in the disrupted birth cohorts per 100,000 girls born, by 2.8-fold from 107 to 302 cases, and by 2.2-fold from 209 to 464 cases under 90% coverage. Furthermore, shifting to GN vaccination helped in reaching the World Health Organization (WHO) elimination threshold. Under GO vaccination with 60% coverage, the age-standardised incidence rate of cervical cancer in India in the long term with vaccination decreased from 11.0 to 4.7 cases per 100,000 woman-years (above threshold), as compared to 2.8 cases (below threshold) under GN with 60% coverage and 2.4 cases (below threshold) under GN with 90% coverage. In conclusion, GN HPV vaccination is an effective strategy to improve the resilience to disruption of cancer prevention programmes and to enhance the progress towards cervical cancer elimination.
format Online
Article
Text
id pubmed-10365835
institution National Center for Biotechnology Information
language English
publishDate 2023
publisher eLife Sciences Publications, Ltd
record_format MEDLINE/PubMed
spelling pubmed-103658352023-07-25 Building resilient cervical cancer prevention through gender-neutral HPV vaccination Man, Irene Georges, Damien Sankaranarayanan, Rengaswamy Basu, Partha Baussano, Iacopo eLife Epidemiology and Global Health The COVID-19 pandemic has disrupted HPV vaccination programmes worldwide. Using an agent-based model, EpiMetHeos, recently calibrated to Indian data, we illustrate how shifting from a girls-only (GO) to a gender-neutral (GN) vaccination strategy could improve the resilience of cervical cancer prevention against disruption of HPV vaccination. In the base case of 5-year disruption with no coverage, shifting from GO to GN strategy under 60% coverage (before disruption) would increase the resilience, in terms of cervical cancer cases still prevented in the disrupted birth cohorts per 100,000 girls born, by 2.8-fold from 107 to 302 cases, and by 2.2-fold from 209 to 464 cases under 90% coverage. Furthermore, shifting to GN vaccination helped in reaching the World Health Organization (WHO) elimination threshold. Under GO vaccination with 60% coverage, the age-standardised incidence rate of cervical cancer in India in the long term with vaccination decreased from 11.0 to 4.7 cases per 100,000 woman-years (above threshold), as compared to 2.8 cases (below threshold) under GN with 60% coverage and 2.4 cases (below threshold) under GN with 90% coverage. In conclusion, GN HPV vaccination is an effective strategy to improve the resilience to disruption of cancer prevention programmes and to enhance the progress towards cervical cancer elimination. eLife Sciences Publications, Ltd 2023-07-24 /pmc/articles/PMC10365835/ /pubmed/37486822 http://dx.doi.org/10.7554/eLife.85735 Text en © 2023, Man et al https://creativecommons.org/licenses/by/4.0/This article is distributed under the terms of the Creative Commons Attribution License (https://creativecommons.org/licenses/by/4.0/) , which permits unrestricted use and redistribution provided that the original author and source are credited.
spellingShingle Epidemiology and Global Health
Man, Irene
Georges, Damien
Sankaranarayanan, Rengaswamy
Basu, Partha
Baussano, Iacopo
Building resilient cervical cancer prevention through gender-neutral HPV vaccination
title Building resilient cervical cancer prevention through gender-neutral HPV vaccination
title_full Building resilient cervical cancer prevention through gender-neutral HPV vaccination
title_fullStr Building resilient cervical cancer prevention through gender-neutral HPV vaccination
title_full_unstemmed Building resilient cervical cancer prevention through gender-neutral HPV vaccination
title_short Building resilient cervical cancer prevention through gender-neutral HPV vaccination
title_sort building resilient cervical cancer prevention through gender-neutral hpv vaccination
topic Epidemiology and Global Health
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10365835/
https://www.ncbi.nlm.nih.gov/pubmed/37486822
http://dx.doi.org/10.7554/eLife.85735
work_keys_str_mv AT manirene buildingresilientcervicalcancerpreventionthroughgenderneutralhpvvaccination
AT georgesdamien buildingresilientcervicalcancerpreventionthroughgenderneutralhpvvaccination
AT sankaranarayananrengaswamy buildingresilientcervicalcancerpreventionthroughgenderneutralhpvvaccination
AT basupartha buildingresilientcervicalcancerpreventionthroughgenderneutralhpvvaccination
AT baussanoiacopo buildingresilientcervicalcancerpreventionthroughgenderneutralhpvvaccination